Patent Document ID: 8623592
Application ID: 13058687
Patent Flag: 1

Claim One:
1. A method of selecting anti-ErbB3 therapy for a patient having a neoplastic tumor, said method comprising: (a) obtaining a sample of the tumor, (b) determining a level of pErbB3 in the sample by indirect measurement that includes: measuring total protein in the sample and levels of (i) at least one receptor selected from ErbB1, ErbB2, and ErbB3 and (ii) at least one of heregulin and betacellulin, (c) comparing the level of pErbB3 in the sample to a level of pErbB3 directly measured in a culture of ACHN cells following culture for 20-24 hours in serum-free medium, and subsequently administering an anti-ErbB3 therapeutic agent to the patient only when the level of pErbB3 determined in the sample is no lower than 50% of the level of pErbB3 measured in the culture of ACHN cells following culture for 20-24 hours in serum-free medium.